Carnegie Capital Asset Management LLC Buys New Stake in Incyte Co. (NASDAQ:INCY)
Carnegie Capital Asset Management LLC Buys New Stake in Incyte Co. (NASDAQ:INCY)
Carnegie Capital Asset Management LLC bought a new stake in shares of Incyte Co. (NASDAQ:INCY – Get Rating) in the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm bought 2,650 shares of the biopharmaceutical company's stock, valued at approximately $223,000.
根据美国证券交易委员会的最新披露，卡内基资本资产管理公司在第二季度购买了Incell Co.(纳斯达克代码：INCY-GET Rating)的新股。该公司购买了2650股这家生物制药公司的股票，价值约22.3万美元。
Other institutional investors also recently bought and sold shares of the company. Parkside Financial Bank & Trust lifted its holdings in shares of Incyte by 91.0% in the 1st quarter. Parkside Financial Bank & Trust now owns 447 shares of the biopharmaceutical company's stock worth $36,000 after acquiring an additional 213 shares during the last quarter. Ellevest Inc. lifted its holdings in shares of Incyte by 210.1% in the 1st quarter. Ellevest Inc. now owns 673 shares of the biopharmaceutical company's stock worth $53,000 after acquiring an additional 456 shares during the last quarter. CKW Financial Group lifted its holdings in shares of Incyte by 33.3% in the 1st quarter. CKW Financial Group now owns 800 shares of the biopharmaceutical company's stock worth $64,000 after acquiring an additional 200 shares during the last quarter. Tobam lifted its holdings in shares of Incyte by 53.3% in the 1st quarter. Tobam now owns 892 shares of the biopharmaceutical company's stock worth $71,000 after acquiring an additional 310 shares during the last quarter. Finally, Parallel Advisors LLC lifted its holdings in Incyte by 22.5% during the 1st quarter. Parallel Advisors LLC now owns 976 shares of the biopharmaceutical company's stock valued at $78,000 after buying an additional 179 shares in the last quarter. 94.74% of the stock is owned by hedge funds and other institutional investors.
其他机构投资者最近也买卖了该公司的股票。Parkside Financial Bank&Trust在第一季度增持了91.0%的Incell股票。Parkside Financial Bank&Trust现在持有这家生物制药公司447股股票，价值3.6万美元，上个季度又购买了213股。Ellevest Inc.在第一季度增持了210.1%的Incell股票。Ellevest Inc.现在持有这家生物制药公司673股股票，价值53,000美元，该公司在上个季度增持了456股股票。长江基建金融集团在第一季度增持了33.3%的Incell股票。长江基建金融集团在上个季度增持了200股后，现在持有这家生物制药公司800股股票，价值6.4万美元。Tobam在第一季度增持了53.3%的Incell股票。在上个季度增持了310股股票后，Tobam现在持有这家生物制药公司892股股票，价值7.1万美元。最后，Parly Advisors LLC在第一季度将其在Incell的持股增加了22.5%。Parly Advisors LLC现在拥有这家生物制药公司976股股票，价值7.8万美元，上个季度又购买了179股。94.74%的股票由对冲基金和其他机构投资者持有。
Wall Street Analysts Forecast Growth
华尔街分析师预测经济增长
A number of equities research analysts recently weighed in on the stock. Guggenheim lowered shares of Incyte to a "neutral" rating in a report on Tuesday, August 9th. SVB Leerink raised their target price on shares of Incyte from $58.00 to $63.00 and gave the company an "underperform" rating in a research report on Wednesday, July 20th. Morgan Stanley cut their price objective on shares of Incyte from $77.00 to $76.00 and set an "equal weight" rating on the stock in a research report on Wednesday, August 3rd. Oppenheimer dropped their target price on shares of Incyte from $109.00 to $98.00 in a research report on Wednesday, August 3rd. Finally, StockNews.com raised shares of Incyte from a "buy" rating to a "strong-buy" rating in a research report on Tuesday, August 30th. One investment analyst has rated the stock with a sell rating, six have given a hold rating, four have given a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of "Hold" and a consensus price target of $84.92.
一些股票研究分析师最近对该股进行了加码。古根海姆在8月9日星期二的一份报告中将Incell的股票评级下调至“中性”。7月20日周三，SVB Leerink在一份研究报告中将Incell的目标价从58.00美元上调至63.00美元，并给出了该公司表现不佳的评级。8月3日，周三，摩根士丹利在一份研究报告中将Incell的目标股价从每股77.00美元下调至每股76.00美元，并对该股设定了“同等权重”的评级。在8月3日星期三的一份研究报告中，奥本海默将Incell的目标股价从109.00美元下调至98.00美元。最后，在8月30日星期二的一份研究报告中，StockNews.com将Incell的股票评级从“买入”上调至“强势买入”。一名投资分析师对该股的评级为卖出，六名分析师给予持有评级，四名分析师给予买入评级，一名分析师对该股给予强烈买入评级。根据MarketBeat.com的数据，该股目前的共识评级为持有，共识目标价为84.92美元。
Insider Buying and Selling at Incyte
Incell的内部买入和卖出
Incyte Trading Down 0.8 %
Incell交易下跌0.8%
Shares of INCY opened at $66.89 on Friday. The company has a current ratio of 3.91, a quick ratio of 3.85 and a debt-to-equity ratio of 0.01. Incyte Co. has a 12-month low of $61.91 and a 12-month high of $84.86. The firm has a 50-day moving average price of $73.33 and a 200 day moving average price of $75.38. The firm has a market capitalization of $14.88 billion, a P/E ratio of 15.74, a P/E/G ratio of 1.09 and a beta of 0.66.
上周五，INCY的股价开盘报66.89美元。该公司的流动比率为3.91，速动比率为3.85，债务权益比率为0.01。Incell Co.股价跌至61.91美元的12个月低点和84.86美元的12个月高位。该公司的50日移动均线价格为73.33美元，200日移动均线价格为75.38美元。该公司的市值为148.8亿美元，市盈率为15.74倍，市盈率为1.09倍，贝塔系数为0.66。
Incyte (NASDAQ:INCY – Get Rating) last announced its quarterly earnings data on Tuesday, August 2nd. The biopharmaceutical company reported $0.85 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.61 by $0.24. Incyte had a net margin of 28.46% and a return on equity of 13.02%. The firm had revenue of $911.40 million during the quarter, compared to analyst estimates of $818.25 million. During the same quarter in the prior year, the firm posted $0.65 earnings per share. Incyte's quarterly revenue was up 29.1% on a year-over-year basis. Sell-side analysts forecast that Incyte Co. will post 2.45 EPS for the current year.
纳斯达克(Incy-Get Rating)上一次公布季度收益数据是在8月2日(星期二)。这家生物制药公司公布本季度每股收益(EPS)为0.85美元，超过分析师普遍预期的0.61美元至0.24美元。Incell的净利润率为28.46%，股本回报率为13.02%。该公司本季度营收为9.114亿美元，而分析师预期为8.1825亿美元。去年同期，该公司公布的每股收益为0.65美元。Incell的季度收入比去年同期增长了29.1%。卖方分析师预计，Incell Co.本年度每股收益将达到2.45欧元。
About Incyte
关于Incell
(Get Rating)
(获取评级)
Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in various liquid and solid tumor types; and ICLUSIG, a kinase inhibitor to treat chronic myeloid leukemia and philadelphia-chromosome positive acute lymphoblastic leukemia.
Incell Corporation是一家生物制药公司，专注于美国和国际上专利疗法的发现、开发和商业化。该公司提供Jakafi，一种治疗骨髓纤维化和真性红细胞增多症的药物；PEMAZYRE，一种成纤维细胞生长因子受体激酶抑制剂，在各种液体和固体肿瘤类型中起致癌作用；以及Iclusig，一种治疗慢性髓细胞白血病和费城染色体阳性的急性淋巴细胞白血病的激酶抑制剂。
Further Reading
进一步阅读
- Get a free copy of the StockNews.com research report on Incyte (INCY)
- Will Wall Street's Enthusiasm About Datadog Lead To Big Gains?
- MarketBeat: Week in Review 9/19 – 9/23
- Why Does Tesla Stock Remain Resilient?
- Are Layoffs At A Small-Cap Tech A Bellwether For Housing Stocks?
- 2 Semiconductor Stocks To Watch For Reversals
- 免费获取StockNews.com关于Incell的研究报告(INCY)
- 华尔街对Datadog的热情会带来巨大的收益吗？
- MarketBeat：回顾一周9/19-9/23
- 为什么特斯拉的股票保持弹性？
- 小盘股的裁员是楼市的晴雨表吗？
- 需要关注的2只半导体类股走势逆转
Want to see what other hedge funds are holding INCY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Incyte Co. (NASDAQ:INCY – Get Rating).
想看看其他对冲基金持有INCY的什么吗？访问HoldingsChannel.com获取Incell Co.(纳斯达克代码：Incy-Get Rating)的最新13F申报文件和内幕交易信息。
Receive News & Ratings for Incyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Incyte and related companies with MarketBeat.com's FREE daily email newsletter.
接受Incell Daily的新闻和评级-在下面输入您的电子邮件地址，通过MarketBeat.com的免费每日电子邮件时事通讯接收对Incell和相关公司的最新新闻和分析师评级的每日简要摘要。
译文内容由第三方软件翻译。